Cargando…
Hepatitis B: future curative strategies
PURPOSE OF REVIEW: Hepatitis B virus (HBV) causes a large proportion of chronic liver disease worldwide. The limited efficiency of current treatments based on the use of nucleotide/nucleoside analogues or interferon-alpha requires the development of new therapeutic tools for the treatment of chronic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232294/ https://www.ncbi.nlm.nih.gov/pubmed/25304392 http://dx.doi.org/10.1097/QCO.0000000000000110 |
_version_ | 1782344544277233664 |
---|---|
author | Bertoletti, Antonio Rivino, Laura |
author_facet | Bertoletti, Antonio Rivino, Laura |
author_sort | Bertoletti, Antonio |
collection | PubMed |
description | PURPOSE OF REVIEW: Hepatitis B virus (HBV) causes a large proportion of chronic liver disease worldwide. The limited efficiency of current treatments based on the use of nucleotide/nucleoside analogues or interferon-alpha requires the development of new therapeutic tools for the treatment of chronic HBV. We summarize the most recent therapeutic strategies designed to directly target HBV-infected hepatocytes or to restore antiviral immunity during chronic HBV infection. RECENT FINDINGS: Novel therapies directly target HBV-infected hepatocytes by inducing covalently closed circular DNA degradation or by inhibiting HBV entry or the expression of viral proteins. In addition, immunotherapeutic approaches may boost HBV-specific T-cell responses or stimulate the intrahepatic innate response. SUMMARY: These new therapeutic approaches have mainly been tested in animal models. In humans, therapeutic strategies could be tailored to different chronic HBV patients in relation to their clinical and virological disease profile. |
format | Online Article Text |
id | pubmed-4232294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-42322942014-11-17 Hepatitis B: future curative strategies Bertoletti, Antonio Rivino, Laura Curr Opin Infect Dis ANTIMICROBIALSL: Edited by Monica A. Slavin and William Irving PURPOSE OF REVIEW: Hepatitis B virus (HBV) causes a large proportion of chronic liver disease worldwide. The limited efficiency of current treatments based on the use of nucleotide/nucleoside analogues or interferon-alpha requires the development of new therapeutic tools for the treatment of chronic HBV. We summarize the most recent therapeutic strategies designed to directly target HBV-infected hepatocytes or to restore antiviral immunity during chronic HBV infection. RECENT FINDINGS: Novel therapies directly target HBV-infected hepatocytes by inducing covalently closed circular DNA degradation or by inhibiting HBV entry or the expression of viral proteins. In addition, immunotherapeutic approaches may boost HBV-specific T-cell responses or stimulate the intrahepatic innate response. SUMMARY: These new therapeutic approaches have mainly been tested in animal models. In humans, therapeutic strategies could be tailored to different chronic HBV patients in relation to their clinical and virological disease profile. Lippincott Williams & Wilkins 2014-12 2014-10-30 /pmc/articles/PMC4232294/ /pubmed/25304392 http://dx.doi.org/10.1097/QCO.0000000000000110 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | ANTIMICROBIALSL: Edited by Monica A. Slavin and William Irving Bertoletti, Antonio Rivino, Laura Hepatitis B: future curative strategies |
title | Hepatitis B: future curative strategies |
title_full | Hepatitis B: future curative strategies |
title_fullStr | Hepatitis B: future curative strategies |
title_full_unstemmed | Hepatitis B: future curative strategies |
title_short | Hepatitis B: future curative strategies |
title_sort | hepatitis b: future curative strategies |
topic | ANTIMICROBIALSL: Edited by Monica A. Slavin and William Irving |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232294/ https://www.ncbi.nlm.nih.gov/pubmed/25304392 http://dx.doi.org/10.1097/QCO.0000000000000110 |
work_keys_str_mv | AT bertolettiantonio hepatitisbfuturecurativestrategies AT rivinolaura hepatitisbfuturecurativestrategies |